Trial Profile
A Phase 1 Study of the CDK4/6 Inhibitor Ribociclib (LEE011) in Combination With the PD-1 Inhibitor PDR001 in Patients With Metastatic Hormone Receptor-positive Breast Cancer and Metastatic Ovarian Cancer
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 05 Apr 2022
Price :
$35
*
At a glance
- Drugs Fulvestrant (Primary) ; Ribociclib (Primary) ; Spartalizumab (Primary)
- Indications Advanced breast cancer; HER2 negative breast cancer; Ovarian cancer
- Focus Adverse reactions
- 16 Mar 2022 Status changed from active, no longer recruiting to discontinued.
- 28 Dec 2020 Status changed from recruiting to active, no longer recruiting.
- 14 Dec 2019 Results (n=16) assessing tolerability of of ribociclib and spartalizumab in patients with metastatic breast cancer and metastatic ovarian cancer, presented at the 42nd Annual San Antonio Breast Cancer Symposium.